{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:21:32Z","timestamp":1792718492116,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T00:00:00Z","timestamp":1516838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["5K23DK103119"],"award-info":[{"award-number":["5K23DK103119"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK043351"],"award-info":[{"award-number":["P30 DK043351"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001063","name":"Crohn's and Colitis Foundation of America","doi-asserted-by":"publisher","award":["Senior Research Award"],"award-info":[{"award-number":["Senior Research Award"]}],"id":[{"id":"10.13039\/100001063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009560","name":"American Gastroenterological Association","doi-asserted-by":"publisher","award":["Pilot Award"],"award-info":[{"award-number":["Pilot Award"]}],"id":[{"id":"10.13039\/100009560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s10620-018-4932-8","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T11:41:54Z","timestamp":1516880514000},"page":"738-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn\u2019s Disease Is Not Associated with Emergence of Novel Inflammatory Pathways"],"prefix":"10.1007","volume":"63","author":[{"given":"Jay","family":"Luther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Gala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj J.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maneesh","family":"Dave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke","family":"Borren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramnik J.","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-1821","authenticated-orcid":false,"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"4932_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20131549.","journal-title":"Lancet"},{"key":"4932_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132:52\u201365.","journal-title":"Gastroenterology"},{"key":"4932_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn\u2019s disease. N Engl J Med. 2007;357:228\u2013238.","journal-title":"N Engl J Med"},{"key":"4932_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/ajg.2008.88","volume":"104","author":"JP Gisbert","year":"2009","unstructured":"Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review. Am J Gastroenterol. 2009;104:760\u2013767.","journal-title":"Am J Gastroenterol"},{"key":"4932_CR5","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","volume":"56","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial. Gut. 2007;56:1232\u20131239.","journal-title":"Gut"},{"key":"4932_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa067594","volume":"357","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn\u2019s disease. N Engl J Med. 2007;357:228\u2013238.","journal-title":"N Engl J Med"},{"key":"4932_CR7","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/ajg.2014.146","volume":"109","author":"X Roblin","year":"2014","unstructured":"Roblin X, Rinaudo M, Del Tedesco E, et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014;109:1250\u20131256.","journal-title":"Am J Gastroenterol"},{"key":"4932_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","volume":"4","author":"M Allez","year":"2010","unstructured":"Allez M, Karmiris K, Louis E, Van Assche G, Ben-Horin S. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4:355\u2013366.","journal-title":"J Crohns Colitis"},{"key":"4932_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.crohns.2010.05.011","volume":"4","author":"A Chowers","year":"2010","unstructured":"Chowers A, Sturm A, Sans M, Papadakis K. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis. 2010;4:367\u2013376.","journal-title":"J Crohns Colitis"},{"key":"4932_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/ard.2007.087288","volume":"68","author":"MJ Harrison","year":"2009","unstructured":"Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209\u2013215.","journal-title":"Ann Rheum Dis"},{"key":"4932_CR11","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1073\/pnas.0408506102","volume":"102","author":"AK Palucka","year":"2005","unstructured":"Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA. 2005;102:3372\u20133377.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4932_CR12","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201315550.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4932_CR13","first-page":"603","volume":"11","author":"I Marafini","year":"2017","unstructured":"Marafini I, Monteleone I, Dinallo V, et al. CCL20 is negatively regulated by TGF-\u03b21 in intestinal epithelial cells and reduced in Crohn\u2019s disease patients with a successful response to mongersen, a Smad7 antisense oligonucleotide. J Crohns Colitis. 2017;11:603\u2013609.","journal-title":"J Crohns Colitis"},{"key":"4932_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nm0617-788d","volume":"23","author":"NR West","year":"2017","unstructured":"West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23:579\u2013589.","journal-title":"Nat Med"},{"key":"4932_CR15","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.1167\/iovs.08-3193","volume":"50","author":"CS Alge-Priglinger","year":"2009","unstructured":"Alge-Priglinger CS, Kreutzer T, Obholzer K, et al. Oxidative stress-mediated induction of MMP-1 and MMP-3 in human RPE cells. Invest Ophthalmol Vis Sci. 2009;50:5495\u20135503.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4932_CR16","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1053\/j.gastro.2015.07.002","volume":"149","author":"P Biancheri","year":"2015","unstructured":"Biancheri P, Brezski RJ, Di Sabatino A, et al. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Gastroenterology. 2015;149:1564\u20131574.","journal-title":"Gastroenterology"},{"key":"4932_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.mehy.2017.04.011","volume":"103","author":"M Gyuraszova","year":"2017","unstructured":"Gyuraszova M, Kovalcikova A, Gardlik R. Association between oxidative status and the composition of intestinal microbiota along the gastrointestinal tract. Med Hypotheses. 2017;103:81\u201385.","journal-title":"Med Hypotheses"},{"key":"4932_CR18","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1172\/JCI75436","volume":"124","author":"Y Haberman","year":"2014","unstructured":"Haberman Y, Tickle TL, Dexheimer PJ, et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. J Clin Invest. 2014;124:3617\u20133633.","journal-title":"J Clin Invest"},{"key":"4932_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/j.1365-2133.2009.09563.x","volume":"162","author":"AE Pink","year":"2010","unstructured":"Pink AE, Fonia A, Allen MH, et al. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol. 2010;162:780\u2013785.","journal-title":"Br J Dermatol"},{"key":"4932_CR20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","volume":"149","author":"JF Brandse","year":"2015","unstructured":"Brandse JF, van den Brink GR, et al. Loss of Infliximab into feces Is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149:350\u2013355.","journal-title":"Gastroenterology"},{"key":"4932_CR21","doi-asserted-by":"publisher","first-page":"E35","DOI":"10.1002\/ibd.22928","volume":"19","author":"JY Kong","year":"2013","unstructured":"Kong JY, Bundell C, Pawlik J, et al. Low trough serum infliximab and antibodies to infliximab in smokers. Inflamm Bowel Dis. 2013;19:E35\u2013E36.","journal-title":"Inflamm Bowel Dis"},{"key":"4932_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","volume":"13","author":"S Ben-Horin","year":"2014","unstructured":"Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24\u201330.","journal-title":"Autoimmun Rev"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-4932-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-4932-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-4932-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T14:39:53Z","timestamp":1589726393000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-4932-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["4932"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-4932-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]},"assertion":[{"value":"27 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SJP have equity interest in Heprotech Inc. MG has equity interest in New Amsterdam Genomics. Ananthakrishnan has served on the scientific advisory boards for Gilead, Takeda, and Abbvie. All other authors have no conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}